{"id":"64cu-dota-tlx592","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"64Cu-DOTA-TLX592 is a radioligand that targets somatostatin receptors, allowing for imaging and treatment of neuroendocrine tumors.","oneSentence":"Somatostatin receptor targeting","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:32:12.839Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neuroendocrine tumors"}]},"trialDetails":[{"nctId":"NCT04726033","phase":"EARLY_PHASE1","title":"64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)","status":"COMPLETED","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2021-08-04","conditions":"Metastatic Prostate Cancer","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["64Cu-TLX592"],"phase":"phase_1","status":"active","brandName":"64Cu-DOTA-TLX592","genericName":"64Cu-DOTA-TLX592","companyName":"Telix Pharmaceuticals (Innovations) Pty Limited","companyId":"telix-pharmaceuticals-innovations-pty-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Somatostatin receptor targeting Used for Neuroendocrine tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}